Indian authorities have ordered Sun Pharma to suspend production of eye-care drugs at a manufacturing plant following quality lapses, the Straits Times reported. The directive targets India's largest pharmaceutical firm. The move amounts to an escalation of regulatory action against the company, according to the Straits Times.
Source: The Straits Times.

